Latest Headlines

  1. CirrusDx Now Offers Susceptibility Testing For Blujepa® (gepotidacin), A Recently Approved Antibiotic For Urinary Tract Infections 6/2/2026

    CirrusDx, Inc. (CirrusDx), an infectious disease laboratory and diagnostics company, today announced it now offers antimicrobial susceptibility testing (AST) for gepotidacin (Blujepa®), GSK's recently approved oral antibiotic for uncomplicated urinary tract infections (uUTIs).

  2. Collaboration To Improve Sustainable Laboratory Workflows 6/1/2026

    Azenta Life Sciences has announced a collaboration with PulpFixin, a pioneering manufacturer of sustainable labware, to help laboratories reduce plastic waste without sacrificing performance, traceability, or operational efficiency.

  3. HNL Lab Medicine Receives Accreditation From The College Of American Pathologists 5/29/2026

    HNL Lab Medicine has been awarded accreditation by the Accreditation Committee of the College of American Pathologists (CAP) following a recent on-site inspection conducted by CAP inspectors.

  4. Labcorp Supports Multi-Institution Trial To Expand Genetic Testing In Colorectal Cancer 5/29/2026

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a collaboration with the Alliance for Clinical Trials in Oncology to advance a national, multicenter clinical trial for patients newly diagnosed with colorectal cancer (CRC).

  5. Leica Biosystems And CellCarta Expand Collaborative Companion Diagnostic Development Model To Accelerate Commercialization Globally 5/29/2026

    CellCarta, a leading global precision medicine laboratory services provider and Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, today announced a strategic partnership to bring a proven companion diagnostic (CDx) joint development model from China to biopharma sponsors globally.

  6. DELFI Diagnostics Receives New York State Department Of Health Clinical Laboratory Permit, Completing Authorization To Serve Health Systems Across All 50 States 5/28/2026

    DELFI Diagnostics, Inc., developer of AI-powered, blood-based tests for cancer detection, today announced it has received a Clinical Laboratory Permit and Test Approval letter from the New York State Department of Health (NYSDOH). With this permit, DELFI is now authorized to offer its FirstLook™ Lung laboratory-developed test (LDT) in New York.

  7. Illumina And SPT Labtech Unveil fireflyGO, Enabling Faster, Simpler Targeted Oncology Research 5/28/2026

    Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research.

  8. Sysmex America Introduces Next Generation XR-Series™ Hematology Solution For Clinical Laboratories 5/28/2026

    Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, has introduced the next generation XR-Series, a hematology solution designed to help busy laboratories deliver fast, reliable results while maintaining efficient workflows.

  9. 20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected By State Of Vermont To Screen Up To 4,500 Firefighters 5/27/2026

    20/20 Biolabs, Inc. (Nasdaq: AIDX) (“20/20 Biolabs” or the “Company”), an early market entrant in AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that its OneTest™ multi-cancer early detection blood (“MCED”) test has been selected as part of a firefighter cancer screening initiative for the state of Vermont in partnership with National Diagnostic Services (“NDS”).

  10. CellCarta And Sonic Healthcare Establish Strategic Partnership To Commercialize Companion Diagnostics Through Lab Network 5/27/2026

    CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a Strategic Partnership with Sonic Healthcare USA, Inc. ("SHUAS" or "Sonic") to launch the first commercial laboratory relationship in CellCarta's Lab Network strategy, designed to support commercialization of companion diagnostics developed through CellCarta's single-site PMA CDx bridging model.